Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis
Open Access
- 3 July 2025
- journal article
- review article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 14 (8) , 1965-1984
Abstract
Introduction To evaluate the outcomes of intravitreal faricimab (IVF; Vabysmo®) in previously treated patients with wet age-related macular degeneration (wAMD), focusing on best available visual acuity (BAVA), central subfield thickness (CST), injection interval, complications, fluid resolution, and reversion rates to prior therapies. Methods The PubMed, Embase, and Google Scholar databases were searched for studies reporting outcomes of treatments for previously treated cases of wAMD. Mean differences (MD) with 95% confidence intervals (CI) were used to compute the effect size of the change in outcomes. Results A total of 29 studies with 2070 patients (1003 women, mean age 78.9 years) and 2128 eyes were included. BAVA and CST were reported in 28 studies, fluid status in 21, injection interval in 14, and reversion rates in 6. Pooled analysis showed significant but modest improvement in BAVA when IVF was given for > 6 months (MD = −0.026 LogMAR, p < 0.05) but not at earlier follow-ups. A similar trend was noted with injection interval extension when IVF was given beyond 6 months (MD = +2.1 weeks, p < 0.05). CST reduction was observed at all time points (overall MD = −37.7 μm, p < 0.05). Complication rates were reported in nine studies, with an overall rate of 1.2%, including retinal pigment epithelium tear, intraocular inflammation, endophthalmitis, and subretinal hemorrhage. Reversion to prior or other anti-vascular endothelial growth factor (anti-VEGF) therapy was reported in six studies, occurring in 23% of eyes. Conclusions We reported the outcomes of utilizing IVF in previously treated cases of wAMD. IVF showed a significant improvement in CST at all time points and in the extension of injection interval. Visual outcomes remained unchanged when followed for less than 6 months but improved significantly but modestly when followed for more than 6 months. Switching to intravitreal faricimab may be a useful treatment option for previously treated patients with wAMD, with a goal of reducing treatment burden and improving treatment efficacy.Keywords
This publication has 51 references indexed in Scilit:
- Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2023
- Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment HistoryOphthalmology and Therapy, 2023
- Faricimab: First ApprovalDrugs, 2022
- Meta-Analysis with R2015
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000
- Evidence for an ATP-driven “proton pump” in rat liver lysosomes by basic dyes uptakeBiochemical and Biophysical Research Communications, 1979